ω-3酸乙酯(Trygg Pharma AS)(Omega-3-acid ethyl esters(Trygg Pharma AS)) - 药物靶点：Lipid x Triglyceride_在研适应症：高脂血症，I型高脂蛋白血症，高甘油三酯血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lotriga Granular、Omega-3 fatty acid ethyl esters、OMEGA-3-ACID ETHYL ESTERS

+ [18]

靶点

Lipid x Triglyceride

作用方式

调节剂

作用机制

脂质调节剂、甘油三酯调节剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Viatris Pty Ltd.Waylis Therapeutics LLC

Takeda Pharmaceutical Co., Ltd.

非在研机构

GSK PlcPronova BioPharma ASA

Pronova Biopharma Norge AS

+ [9]

权益机构

Woodward Pharma Services LLC

GlaxoSmithKline LLC

最高研发阶段批准上市

首次获批日期

美国 (2004-11-10),

高甘油三酯血症

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构/序列

分子式C46H70O4

InChIKeyDTMGIJFHGGCSLO-FIAQIACWSA-N

CAS号861006-80-6

关联

390

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床试验

NCT06434948

/ Enrolling by invitation临床2期IIT

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery: a Prospective, Randomized, Controlled Trial

The purpose of this study is to determine whether giving omega-3 fatty acids prior to and after cardiac bypass surgeries decreases the incidence of postoperative delirium in patients aged 65 and over.

开始日期2025-10-15

申办/合作机构

University of Missouri

NCT06478290

/ Not yet recruitingN/A

Pilot Assessment of the Safety of a Combination of Curcumin, Omega-3, and Vitamin D Supplements (PASCOD) in ACPA+ Individuals

The goal of this clinical trial is to determine if the level of Anti-cyclic citrullinated peptide antibody (ACPA) is altered after taking curcumin, omega-3, and vitamin D supplements (COD) for 3 months. It will also determine the safety and tolerability of COD in the study population. This trial aims to answer the following questions: Does COD consumption lower the level of ACPA in the study participants? What side effects will participants have after taking COD? This pilot study will have an open label pre-post design and study participants will know that they are using each of the three supplements. Participants will: Take the combination of supplements following an evening meal, for 84 consecutive days. Visit the clinic/study team twice during the study duration on days 0 and 84 for checkups and tests. Keep a diary of study treatment consumption.

开始日期2025-10-01

申办/合作机构

University of Manitoba

[+1]

CTRI/2025/06/088500

/ Not yet recruiting临床4期IIT

Scaling and root planing with or without omega 3 supplimentation in management of chronic periodontitis a comparative study - NIL

开始日期2025-06-21

申办/合作机构-

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床结果

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的转化医学

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的专利（医药）

登录后查看更多信息

3,038

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的文献（医药）

2025-12-31·Epigenetics

Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines

Article

作者: Kaul-Ghanekar, Ruchika ; Raina, Prerna ; Ulhe, Amrita ; Chaudhary, Amol

Cervical cancer, the fourth most common cancer globally and the second most prevalent cancer among women in India, is primarily caused by Human Papilloma Virus (HPV). The association of diet with cancer etiology and prevention has been well established and nutrition has been shown to regulate cancer through modulation of epigenetic markers. Dietary fatty acids, especially omega-3, reduce the risk of cancer by preventing or reversing the progression through a variety of cellular targets, including epigenetic regulation. In this work, we have evaluated the potential of ALA (α linolenic acid), an ω-3 fatty acid, to regulate cervical cancer through epigenetic mechanisms. The effect of ALA was evaluated on the regulation of histone deacetylases1, DNA methyltransferases 1, and 3b, and global DNA methylation by ELISA. RT-PCR was utilized to assess the expression of tumor regulatory genes (hTERT, DAPK, RARβ, and CDH1) and their promoter methylation in HeLa (HPV18-positive), SiHa (HPV16-positive) and C33a (HPV-negative) cervical cancer cell lines. ALA increased DNA demethylase, HMTs, and HATs while decreasing global DNA methylation, DNMT, HDMs, and HDACs mRNA expression/activity in all cervical cancer cell lines. ALA downregulated hTERT oncogene while upregulating the mRNA expression of TSGs (Tumor Suppressor Genes) CDH1, RARβ, and DAPK in all the cell lines. ALA reduced methylation in the 5' CpG island of CDH1, RARβ, and DAPK1 promoters and reduced global DNA methylation in cervical cancer cell lines. These results suggest that ALA regulates the growth of cervical cancer cells by targeting epigenetic markers, shedding light on its potential therapeutic role in cervical cancer management.

2025-11-01·POULTRY SCIENCE

Cecal bacterial communities and lung immunity in layers fed omega-3 fatty acids or yeast bioactives under different space allowance

Article

作者: Diarra, Moussa S ; Clairmont, Lindsey ; Kiarie, Elijah G ; Waliaula, Paul Kibaba ; Lepp, Dion ; Yin, Xinhua

The poultry-rearing environment and diet can influence gut microbiota and immunity. However, the long-term effects of early-life nutritional interventions on gut heath in layers under various spacing allowances (SA) are not well understood. This study investigated how early-life dietary yeast bioactives (YB) or co-extruded full-fat flaxseed, a source of omega-3 fatty acids (N-3 FA), from placement to 16 weeks of age (woa) influenced the development of cecal microbiota and immune function in Lohmann LSL Lite pullets reared under different SA, with follow-up to 72 woa. The experiment involved 2,832 newly hatched chicks reared in an enriched cage system under high (HSA, 348 cm²/bird) or low (LSA, 284 cm²/bird) SA and fed either control diet (C), C + 3 % N-3 FA, or C + 0.05 % YB. Ceca were sampled at 4, 8, 16, 35, and 72 woa for bacterial plate counts, 16S rRNA sequencing, and short-chain fatty acid (SCFA) quantification. Lungs were analyzed for immune gene expression. At 4 and 16 woa, β-diversity (P = 0.01) revealed dissimilarity between the bacterial communities of birds under HSA and LSA groups. High Bacteroides abundances, propionic and iso-butyric acids concentrations were observed in LSA at both sampling points (P<0.05). At 16 woa, the highest and lowest n-butyrate concentrations were noted in N-3 FA- and control-fed birds, respectively (P < 0.05), regardless of SA. Barnesiellaceae positively correlated with n-valeric and acetic acid in N-3 FA-fed birds at 4 woa. In YB-fed pullets, Lactobacillaceae and Enterobacteriaceae showed a positive correlation with n-butyric acid. In the lungs, about 15 genes, including IL1β,IL2, and IL8, were differentially expressed depending on SA and diets (P<0.05). Early dietary YB or N-3 FA under different SA modulated cecal bacterial community diversity and structure, SCFA profiles, and enhanced lung immune responses in layer.

2025-11-01·JOURNAL OF AFFECTIVE DISORDERS

Neuroticism, omega-3 fatty acids, and risk of incident dementia

Article

作者: Amin, Najaf ; van Duijn, Cornelia ; Gao, Yaqing ; Littlejohns, Thomas J

BACKGROUND:

High levels of neuroticism are associated with an increased risk of dementia, yet the underlying biological mechanisms remain poorly understood. Investigating the role of metabolites, the downstream products of metabolic processes, may offer valuable insights into this association.

METHODS:

In 215,624 dementia-free UK Biobank participants aged 40-69 years, we assessed neuroticism's associations with 249 nuclear magnetic resonance-measured metabolites using linear regression. Metabolites reaching Bonferroni-corrected significance were further tested for associations with incident all-cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) using Cox proportional-hazards regression, and with white matter hyperintensities volume using linear regression. Causality in significant observational relationships was evaluated through two-sample Mendelian randomization.

RESULTS:

Neuroticism was significantly associated with 119 out of 249 metabolites (Bonferroni-adjusted p < 0.05). Among these, five metabolites involved in fatty acid metabolism showed consistent directional associations with both neuroticism and incident all-cause dementia. Specifically, four metabolites, including docosahexaenoic acid (DHA), DHA% of total fatty acids, omega-3 % of total fatty acids, and degree of unsaturation, were associated with lower neuroticism levels and a decreased risk of incident dementia. Conversely, the omega-6/omega-3 ratio was positively associated with both neuroticism and dementia risk. Associations between these five metabolites and VaD were stronger than those with AD. Mendelian randomization analysis suggested that high levels of neuroticism reduce DHA levels, which, in turn, contribute to white matter pathology, a hallmark of VaD.

CONCLUSIONS:

Neuroticism is associated with lower levels of omega-3 fatty acids, particularly DHA, which may increase dementia risk, primarily through cerebrovascular mechanisms.

84

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的新闻（医药）

2025-08-18

·PRNewswire

ZINZINO AB (PUBL.): New study unveils global snapshot on Omega-3 deficiency - and why high-precision testing plus an enhanced formula can close the gap

GOTHENBURG, Sweden, Aug. 18, 2025 /PRNewswire/ -- A groundbreaking study published in Lipids in Health and Disease (9 August 2025) reveals that the vast majority of individuals worldwide have insufficient omega-3 levels, despite widespread supplement use, highlighting a critical global health need. The analysis, covering more than 590,000 whole-blood dried blood spot samples, was conducted using Zinzino's proprietary BalanceTest database – the world's largest of its kind to date. Key insights from the study: Widespread omega-3 deficiency: Across diverse regions, participants—including those reporting use of omega-3 supplements – frequently failed to reach optimal levels, with consistently elevated omega-6:3 ratios. Zinzino's omega-3 supplement BalanceOil+ was not part of the evaluation. Regional disparities: Coastal diets rich in seafood showed relatively higher omega-3 status, while inland regions with typical Western diets lagged behind. Testing is essential: These results validate the necessity of measuring rather than guessing – objective blood testing like the BalanceTest is crucial to evaluate nutritional status accurately and guide effective interventions. A powerful combination: Test-based nutrition + advanced delivery "This study is a milestone for us," says Dr. Colin Robertson, Chief Product Officer at Zinzino. "For the first time, we have published data in a peer-reviewed scientific journal – Lipids in Health and Disease – which has been a collaboration between our in-house research team, our Scientific Advisory Board, and the independent analytical contract lab Vitas AS. This is not just a publication; it's hard evidence that we are shaping global nutrition science with real-world evidence from a global population." "The world has moved beyond one-size-fits-all solutions. This study underscores that many supplements in the market fall short – and targeted, scientifically designed formulations paired with accurate, large-scale measurement are critical to closing the nutritional gap. "The BalanceTest provides a scientifically validated, standardized, and scalable method to assess omega-3 status and omega-6:3 balance – all from a simple dried blood spot sample. It delivers precise, reproducible results that allow both individuals and health professionals to track nutritional status and guide targeted, evidence-based interventions," Dr. Robertson concludes. Why this matters now While the study establishes an essential baseline for global omega3 status, the next frontier lies in improving supplementation. That's where Zinzino's BalanceOil comes in—a carefully crafted, proprietary blend (60% high-quality fish oil rich in EPA and DHA, 40% extra virgin olive oil), fortified with polyphenols, natural tocopherols, and vitamin D. This design enhances oxidative stability and bioavailability, aiming to support better omega-3 blood levels and balanced fatty acid ratios. With omega-3 levels tied to cognitive function, cardiovascular health, and inflammation control, the implications of this study are both clinical and strategic. Some populations eat fish regularly, others hardly at all. And while supplementation is promoted, the actual omega-3 status of individuals – and entire populations – has been largely unknown due to lack of objective measurement. Testing offers a roadmap: start with a scientific measurement (BalanceTest), follow up with a superior formulation (BalanceOil), and continue supplementing and testing to close the nutritional gap. Public health guidelines recommend higher intakes of omega-3, but diets vary enormously by culture and country. "Our results provide the most comprehensive picture to date of omega-6:3 balance worldwide," says Dr. Martina Torrissen, Research & Development Specialist at Zinzino and co-author of the article. "By identifying critical gaps, this research helps guide public health priorities and empowers companies like Zinzino to deliver personalized solutions that address real needs in global nutrition," Dr. Torrissen concludes. The motto 'Test, don't guess' is central to Zinzino's test-based nutrition philosophy and represents a leap forward in personalized health and wellness. "For Zinzino, this is more than science – it validates our mission," says CEO Dag Pettersen. "By combining personalized, test-based nutrition with one of the world's largest fatty acid databases, we are not only transforming individual lives but also shaping the future of preventive health on a global scale." "One of our greatest strengths is that the BalanceTest can literally measure the world," says Pettersen. "Unlike surveys or population samples based on blood plasma, which require complex lab work, we have developed a reliable, highly sensitive tool that measures people's health status — right from their own homes." About BalanceTest The BalanceTest is an at-home dried blood spot (DBS) test that delivers reliable readings of omega-3 status and fatty acid balance. Administered via a fingertip sample, it's processed by Vitas, an independent, GMP-certified lab in Oslo, Norway, delivering scientific clarity on health markers like Omega-3 index, cell membrane fluidity, and mental resilience. About BalanceOil BalanceOil+ is a purpose-built omega-3 supplement featuring a 60:40 fish oil plus extra virgin olive oil ratio, supplemented with vitamin D and natural tocopherols for enhanced stability and absorption, designed to help users achieve and sustain a balance of omega-6 and omega-3 blood levels linked with health benefits. About Zinzino Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available in more than 100 markets across the world. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, and Australia. Publication details Title: Global variations in omega-3 fatty acid status and omega-6:omega-3 ratios: insights from >500,000 wholeblood dried blood spot samples Journal: Lipids in Health and Disease (2025), Article Number: 260 For more information: Dag Pettersen CEO Zinzino +47 (0) 932 25 700, [email protected] Pictures for publication free of charge: [email protected] Certified Adviser: DNB Carnegie Investment Bank AB (publ.) This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-06-09

·九洲药业

喜报!康川济医药助力合作伙伴二十碳五烯酸乙酯软胶囊获批上市

据NMPA发布的药品批准证明文件送达信息显示，新华制药的二十碳五烯酸乙酯软胶囊（0.5g和1.0g）取得国家药品监督管理局下发的《药品注册证书》，获得上市许可。康川济医药为该产品提供了研发相关服务。二十碳五烯酸乙酯软胶囊属于高纯度的Omega-3脂肪酸乙酯类药物，能够有效抑制肝脏中胆固醇的合成，降低血液中胆固醇和甘油三酯水平，进而达到降低血脂的目的。大量临床研究表明，其在控制血脂方面效果显著，在控制饮食的基础上，用于降低重度高甘油三酯血症（≥500mg/dL）成年患者的甘油三酯（TG）水平，4g /天的剂量应用 12 周，可降低甘油三酯水平约 16%-26% 。不仅如此，它还在心血管疾病预防方面展现出突出优势。发表于《新英格兰医学杂志》的重磅研究 REDUCE - IT 表明，对于他汀治疗后仍存在高甘油三酯血症的心血管疾病高危患者，使用二十碳五烯酸乙酯能显著降低主要不良心血管事件相对风险达25%。康川济医药南京康川济医药科技有限公司成立于2013年，浙江九洲药业股份有限公司(股票简称:九洲药业，股票代码: 603456.SH)的控股子公司，业务范围覆盖创新药、改良型新药、高端仿制药研发及技术咨询和代理注册等；研发团队150余人，硕士学历占比30%以上；研发设备配备齐全，满足新药开发各阶段要求。依托九洲药业，我们可以提供原料药+制剂的CDMO一站式服务。联系我们地址：南京市江宁区文芳路199号5幢二层商务合作：文章转载自南京康川济

申请上市

2025-06-05

·PRNewswire

Lupus Foundation of America Awards Summer Fellowship Grants to Seven Young Scientists Advancing Lupus Research

WASHINGTON, June 5, 2025 /PRNewswire/ -- The Lupus Foundation of America is proud to announce the seven recipients of the 2025 Gina M. Finzi Memorial Student Summer Fellowship Program (Finzi). This program supports undergraduate, graduate, and medical students conducting lupus-focused research under the guidance of experienced mentors at academic institutions in the US, Canada or Mexico. Its purpose is to inspire medical and graduate students to pursue lupus research, helping to build the future pipeline of experts across North America. This year's Finzi Fellows will spend the summer investigating unanswered questions in lupus including: How skin lesions heal – uncovering the biological steps the body takes to resolve lupus-related skin damage. The brain and nerves in lupus – exploring how lupus affects the brain, spinal cord, and nerves, including changes in brain structure and function. Mental health and self-care – studying how chronic stress from "superwoman schema" affects a patient's ability to engage in self-management. Lupus in the kidneys – identifying the biological and social factors that drive the development of lupus nephritis (lupus-related kidney disease), a serious kidney complication. The role of diet and nutrients – two studies in this area, examining how dietary compounds like omega-3 fatty acids influence immune cells and disease activity, as well as how nutrition may impact symptoms and flares. Lupus and the X chromosome – investigating how changes in genes located on the X chromosome may increase lupus risk, especially in women. "Students pursuing their graduate or medical education in biomedical fields are poised to become the next generation of scientists, and recognition of their efforts through the Gina M. Finzi Student Summer Fellowship Program, and the excitement for their research, helps inspire students to continue investigations in the field of lupus and autoimmunity in their future careers," shared Montserrat Anguera, PhD, Associate Professor, Department of Biomedical Sciences, University of Pennsylvania and 2025 Finzi grantee mentor. Throughout the fellowship, Finzi recipients work closely with seasoned clinical investigators and biomedical scientists who provide guidance and foster their development as emerging scientists. This mentorship is a vital part of the program, offering essential support as students begin to shape their careers in lupus research. Launched in 1984, the Gina M. Finzi Memorial Student Summer Fellowship Program was established in memory of Gina M. Finzi, daughter of former Lupus Foundation of America President Sergio Finzi, PhD. Many past fellows have gone on to become leaders in the field, advancing groundbreaking research in lupus. "The future of lupus research is in the hands of the students that will be ushering in the next breakthroughs in the field," shared Joy Buie, Ph.D, MSCR, RN, Vice President of Research at Lupus Foundation of America. "The Gina M. Finzi Memorial Student Summer Fellowship Program is uniquely positioned to ensure investments are made in the brightest, most innovative young minds. With guidance from mentors, these Finzi Fellows will gain the experiences needed to support a research career focused on closing gaps in lupus diagnosis, treatment and care." The research conducted by Finzi Fellows will contribute to a variety of crucial areas within the lupus field: Grace Crossland Dartmouth College, Geisel School of Medicine Project Title: Defining the role of mucosal-associated invariant T (MAIT) cells in cutaneous lupus erythematosus Mentor: Sladjana Skopelja-Gardner, PhD Vanessa Estrada Department of Microbiology, Genetics, & Immunology, Michigan State University Project Title: Omega-3 Fatty Acids: Omega-3 Effects on Interferon Gene Methylation in Lupus Macrophages Mentor: James J. Pestka, PhD Rohan Gupta The Feinstein Institutes for Medical Research Project Title: Determining the Role of the Aryl Hydrocarbon Receptor (AHR) in NPSLE Mentor: Betty Diamond, MD Jerik Leung Emory University Project Title: Using Photovoice to Understand Self-Management Behaviors in Lupus Mentors: S. Sam Lim, MD, MPH; Cam Escoffery, PhD, MPH, CHES Sara Smith The Regents of University of California, San Francisco Project Title: Uncovering the Molecular Underpinnings of Lupus Nephritis with Multi-Omic Analysis Mentor: Gabriela K. Fragiadakis, PhD Emma Welter The Trustees of the University of Pennsylvania Project Title: Investigating the Impact of Lupus-Like Disease on the Inactive X Chromosome in Age-Associated B Cells Mentor: Montserrat Anguera, PhD Jin Xuan Zhou Hospital for Sick Children, Toronto Project Title: Diffusion Tensor Imaging Metrics and Neurocognitive Function in cSLE Mentor: Andrea Knight, MD, MSCE Learn more about the 2025 Gina M. Finzi Memorial Student Summer Fellowship recipients, here. About the Lupus Foundation of America: The Lupus Foundation of America is the only national force devoted to solving the mystery of lupus, one of the world's cruelest, most unpredictable, and devastating diseases, while giving caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus. About Lupus: Lupus is an unpredictable and misunderstood autoimmune disease that ravages different parts of the body. It is difficult to diagnose, hard to live with, and a challenge to treat. Lupus is a cruel mystery because it is hidden from view and undefined, has a range of symptoms, hits out of nowhere, and has no known cause and no known cure. Its health effects can range from a skin rash to a heart attack. Lupus is debilitating and destructive, and can be fatal, yet research on lupus remains underfunded relative to its scope and devastation. MEDIA CONTACT Shannon Brown [email protected] 202-763-5485 SOURCE Lupus Foundation of America, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05255	ω-3酸乙酯(Trygg Pharma AS)	C10AX06	DB09539

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高脂血症	日本	Takeda Pharmaceutical Co., Ltd.	2012-09-28
I型高脂蛋白血症	澳大利亚	Viatris Pty Ltd.	2010-08-05
高甘油三酯血症	美国	Waylis Therapeutics LLC	2004-11-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
IV型高脂蛋白血症	临床3期	中国	AbbVie Pharmaceuticals GmbH	2016-09-19
IV型高脂蛋白血症	临床3期	中国	Pronova Biopharma Norge AS	2016-09-19
IV型高脂蛋白血症	临床3期	中国	GMPack ApS	2016-09-19
IV型高脂蛋白血症	临床3期	中国	雅培贸易（上海）有限公司	2016-09-19
II型高脂蛋白血症	临床3期	挪威	Pronova BioPharma ASA	2013-03-01
心脏衰竭	临床3期	美国	GSK Plc	2010-01-01
糖尿病	临床3期	美国	GSK Plc	2009-09-01
高血压	临床3期	美国	GSK Plc	2009-09-01
心肌梗塞	临床3期	美国	GSK Plc	2008-08-01
心房颤动	临床3期	美国	GSK Plc	2006-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03406897 (POSEIDON, CTgov)	临床1/2期	1型糖尿病 \| 低血糖	27	Omega 3 fatty acid+cholecalciferol (Omega-3 and Vitamin D Combination)	繭鑰觸壓蓋淵願衊齋壓(醖糧鑰積壓窪網夢醖齋) = 醖廠積遞範壓壓醖鏇築願膚窪廠鹹憲簾鏇鏇壓 (顧餘觸醖淵廠網築網鹽, 築築觸夢齋範鏇顧鹽製 ~ 選糧選積蓋鹽窪蓋醖構) 更多	-	2025-09-17
				cholecalciferol (Vitamin D Only)	繭鑰觸壓蓋淵願衊齋壓(醖糧鑰積壓窪網夢醖齋) = 繭糧窪鹹積夢膚觸齋顧願膚窪廠鹹憲簾鏇鏇壓 (顧餘觸醖淵廠網築網鹽, 積夢窪淵簾積艱範積衊 ~ 鬱製鬱遞構膚鹽廠膚鬱) 更多
NCT00678743 (CTgov)	临床4期	血脂障碍	17	simvastatin+Omacor	窪獵築顧鬱憲壓壓繭餘(蓋窪壓願構夢憲鏇鹽廠) = 艱積鏇遞膚構窪獵獵範齋餘鬱蓋淵廠糧遞淵膚 (壓積構顧淵觸範遞鑰廠, 遞齋襯蓋鹽壓構製齋獵 ~ 顧範襯鬱構獵淵網壓窪) 更多	-	2025-05-29
NCT04181593 (CTgov)	临床3期	干眼综合征	322	Omega 3 fatty acid (OmegaD)	範蓋鏇衊積鑰網簾艱繭(顧壓積襯夢蓋衊醖鹽窪) = 膚觸範顧窪淵獵廠鹽窪醖鹽淵築衊鏇艱選衊範 (淵構蓋積顧襯鑰夢願選, 17.1) 更多	-	2024-07-29
				Placebos (Placebo)	範蓋鏇衊積鑰網簾艱繭(顧壓積襯夢蓋衊醖鹽窪) = 膚膚淵鬱醖廠遞醖餘觸醖鹽淵築衊鏇艱選衊範 (淵構蓋積顧襯鑰夢願選, 13.2) 更多
NCT00746811 (CTgov)	临床4期	原发性高胆固醇血症	32	P-OM3 (P-OM3)	觸餘蓋選繭衊窪鹽獵簾(糧齋艱繭壓築選鹹窪壓) = 鬱窪網廠願構築廠鑰簾艱壓顧遞鑰構壓鹽選製 (觸夢夢憲鏇製廠遞糧觸, 1.8) 更多	-	2024-05-08
				Placebo (Placebo)	觸餘蓋選繭衊窪鹽獵簾(糧齋艱繭壓築選鹹窪壓) = 繭壓齋鬱願壓鏇顧廠獵艱壓顧遞鑰構壓鹽選製 (觸夢夢憲鏇製廠遞糧觸, 1.6) 更多
NCT04198805 (PUVENAFLD, CTgov)	临床2期	非酒精性脂肪性肝炎	205	Omega-3 fatty acid+Vitamin E (DHA EE (1.89 g) and Vitamin E (1000 mg))	蓋鬱夢醖顧壓窪夢鑰窪(遞選夢鏇築壓襯淵願鬱) = 積廠糧鑰築鹹餘鹹餘鏇糧鑰膚窪餘夢憲衊遞鬱 (淵衊醖齋遞簾壓積廠醖, 26.4) 更多	-	2023-05-25
				Placebo (Placebo)	蓋鬱夢醖顧壓窪夢鑰窪(遞選夢鏇築壓襯淵願鬱) = 構淵淵顧夢夢壓繭膚構糧鑰膚窪餘夢憲衊遞鬱 (淵衊醖齋遞簾壓積廠醖, 18.2) 更多
NCT03345550 (OPTIMA, CTgov)	临床2期	脑震荡	44	Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (Omega-3 Polyunsaturated Fatty Acid Treatment Arm)	積顧蓋鬱壓獵鑰選齋衊(齋壓繭選夢齋鏇鬱鹽製) = 醖製鏇繭窪獵觸築艱壓鹽顧壓遞蓋糧蓋憲積夢 (範鑰齋築繭蓋夢觸築鬱, 積夢夢願範鏇簾醖淵製 ~ 餘蓋淵夢鏇觸獵顧遞鏇) 更多	-	2023-05-23
				Placebo - Cap (Placebo Arm)	積顧蓋鬱壓獵鑰選齋衊(齋壓繭選夢齋鏇鬱鹽製) = 簾淵願積鬱獵選鹽獵鑰鹽顧壓遞蓋糧蓋憲積夢 (範鑰齋築繭蓋夢觸築鬱, 鑰鹽構鬱襯鬱鑰鏇願鹹 ~ 選壓醖餘襯築鏇壓積襯) 更多
NCT01669915 (VITAL-Cog, CTgov)	N/A	认知功能障碍	3,424	Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Active Vitamin D)	積獵繭廠淵繭選壓獵糧(壓憲膚艱夢憲廠顧淵憲) = 繭鑰鑰憲膚範憲選窪夢築願選網願願廠繭淵膚 (觸遞鏇範襯醖鏇構製鬱, 0.01) 更多	-	2023-04-21
				Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Vitamin D Placebo)	積獵繭廠淵繭選壓獵糧(壓憲膚艱夢憲廠顧淵憲) = 願簾窪繭範觸鏇齋淵顧築願選網願願廠繭淵膚 (觸遞鏇範襯醖鏇構製鬱, 0.01) 更多
NCT01813006 (EUDRACTNR 2012-000505-68, Pubmed \| Scand J Clin Lab Invest)	临床3期	II型高脂蛋白血症	34	Omega-3 polyunsaturated fatty acid supplement	製艱製齋鑰醖網膚夢觸(餘築憲鏇醖廠齋襯選選) = 鹽衊膚築膚窪醖獵淵鏇衊餘鏇顧鹽築糧糧鹹壓 (壓簾願積範築積齋淵醖, [ ~ 13, 6])	-	2023-03-31
NCT01696435 (VITAL \| VITAL-DEP, CTgov)	N/A	-	18,353	Fish oil placebo+vitamin D3 (Vitamin D + Fish Oil Placebo)	醖願選遞簾窪製餘積廠(齋壓衊廠網顧選襯憲蓋) = 積遞襯襯築鑰築齋鏇夢網蓋壓網範製鹹窪獵壓 (鏇窪鑰糧膚鏇選遞積範, 製蓋齋憲鑰範襯壓鑰衊 ~ 繭顧構網鏇淵鬱繭築繭) 更多	-	2023-03-14
				Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil)	醖願選遞簾窪製餘積廠(齋壓衊廠網顧選襯憲蓋) = 築願繭鬱艱選鑰齋廠餘網蓋壓網範製鹹窪獵壓 (鏇窪鑰糧膚鏇選遞積範, 製廠衊壓艱築網淵壓製 ~ 鏇選構襯鏇鏇淵夢餘築) 更多
NCT04495816 (CTgov)	临床2期	新型冠状病毒感染 \| 嗅觉丧失	139	Omega-3 Fatty Acid Supplement (Omega-3)	鹹糧壓淵築衊餘鹹願膚(鹹膚窪鑰齋艱鏇糧願膚) = 廠鏇鑰憲網繭醖製壓艱鹽築廠壓鬱鏇糧窪鏇窪 (網鏇願壓構艱膚襯顧網, 1.94) 更多	-	2023-01-31
				Placebo/Control (Placebo/Control)	鹹糧壓淵築衊餘鹹願膚(鹹膚窪鑰齋艱鏇糧願膚) = 鹹鏇夢襯夢憲襯獵製廠鹽築廠壓鬱鏇糧窪鏇窪 (網鏇願壓構艱膚襯顧網, 1.88) 更多